Luis Rosado Carrillo, MD
Cardiovascular Disease · Guaynabo, PRNPI 1821009366
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $152,706 of the $173,492 with a category attached, or 88.0%. Amgen accounts for 66.9% of it on its own, with 19 other manufacturers making up the rest. Among cardiovascular disease clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 267 payments — averaging $649.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$116K
- E.r. Squibb & Sons, L.L.C.$47K
- Medtronic$5K
- Johnson & Johnson$3K
- Abbott$847
- Boehringer Ingelheim$513
- plus $1K from 14 others
What the payments were for
- Consulting fees$3,0202%
- Speaking & faculty fees$152,70688%
- Travel & lodging$4,4343%
- Food & beverage$13,2748%
- Education$570%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 120 | $116,065 |
| E.r. Squibb & Sons, L.L.C. | 52 | $47,023 |
| Medtronic(2 entities) | 35 | $4,843 |
| Johnson & Johnson | 10 | $2,869 |
| Abbott | 8 | $847 |
| Boehringer Ingelheim | 12 | $513 |
| AstraZeneca | 7 | $301 |
| Merck | 3 | $241 |
| Impulse Dynamics (USA) Inc. | 1 | $122 |
| Pfizer Pharmaceuticals LLC | 2 | $119 |
| Lilly USA, LLC | 1 | $119 |
| Novartis | 1 | $100 |
| Boston Scientific | 1 | $90 |
| Bayer Puerto Rico Inc. | 3 | $73 |
| PBG Puerto Rico LLC | 4 | $51 |
| Bayer | 1 | $32 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Sobi, Inc | 1 | $23 |
| Pfizer | 2 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$173,492 in reported general payments places this provider in the 95th percentile of 267 cardiovascular disease providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 434 | $303,386 |
| XareltoRivaroxaban | 140 | $113,051 |
| EntrestoSacubitril/Valsartan | 119 | $82,193 |
| JardianceEmpagliflozin | 73 | $58,510 |
| Repatha SureclickEvolocumab | 78 | $44,034 |
| FarxigaDapagliflozin Propanediol | 61 | $35,785 |
| SynthroidLevothyroxine Sodium | 192 | $21,221 |
| Metoprolol Succinate | 896 | $18,803 |
| BrilintaTicagrelor | 26 | $16,878 |
| TradjentaLinagliptin | 20 | $13,697 |
| JanuviaSitagliptin Phosphate | 13 | $11,978 |
| Losartan Potassium | 804 | $11,470 |
| Irbesartan-HydrochlorothiazideIrbesartan/Hydrochlorothiazide | 227 | $11,416 |
| Irbesartan | 267 | $10,287 |
| Atorvastatin Calcium | 734 | $10,195 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $14 | $303,386434 claims |
| Johnson & JohnsonXarelto | $2,869 | $113,051140 claims |
| NovartisEntresto | $100 | $82,193119 claims |
| Boehringer IngelheimJardiance, Tradjenta | $513 | $72,20793 claims |
| AstraZenecaFarxiga, Brilinta | $301 | $52,66287 claims |
| MerckJanuvia, Janumet | $241 | $18,88524 claims |
| Sanofi-aventis U.S. LLCPlavix | $23 | $3,19411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 267 cardiovascular disease providers in Puerto Rico.
Other cardiovascular disease in Guaynabo
- Denis Ruiz SerranoGuaynabo$66K
- Jose Reyes PenaGuaynabo$11K
- Karen Rodriguez MaldonadoMayaguez$231K
- Jose NovoaBayamon$209K
- Manuel GuzmanSan Juan$203K
- Jorge GonzalezCaguas$114K
- Luis GelyCaguas$89K
- Luis Renta RosaCarolina$83K
- Ramon PereaSan Juan$68K
- Francisco Merced-OrtizSan Juan$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.